Portal de investigação
Soluble urokinase-type plasminogen activator receptor improves early risk stratification in cardiogenic shock
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- Hongisto, M
- Lassus, J
- Tarvasmäki, T
- Sans-Roselló, J
- Tolppanen, H
- Kataja, A
- Jäntti, T
- Sabell, T
- Banaszewski, M
- Parissis, J
- Jurkko, R
- Spinar, J
- Castrén, M
- Mebazaa, A
- Masip, J
- Harjola, VP
- Network, CSIATG
Unidades de investigação
Abstract
Aims Soluble urokinase-type plasminogen activator receptor (suPAR) is a biomarker reflecting the level of immune activation. It has been shown to have prognostic value in acute coronary syndrome and heart failure as well as in critical illness. Considering the complex pathophysiology of cardiogenic shock (CS), we hypothesized suPAR might have prognostic properties in CS as well. The aim of this study was to assess the kinetics and prognostic utility of suPAR in CS. Methods and results SuPAR levels were determined in serial plasma samples (0-96 h) from 161 CS patients in the prospective, observational, multicentre CardShock study. Kinetics of suPAR, its association with 90-day mortality, and additional value in risk-stratification were investigated. The median suPAR-level at baseline was 4.4 [interquartile range (IQR) 3.2-6.6)] ng/mL. SuPAR levels above median were associated with underlying comorbidities, biomarkers reflecting renal and cardiac dysfunction, and higher 90-day mortality (49% vs. 31%; P = 0.02). Serial measurements showed that survivors had significantly lower suPAR levels at all time points compared with nonsurvivors. For risk stratification, suPAR at 12 h (suPAR(12h)) with a cut-off of 4.4 ng/mL was strongly associated with mortality independently of established risk factors in CS: OR 5.6 (95% CI 2.0-15.5); P = 0.001) for death by 90 days. Adding suPAR(12h) > 4.4 ng/mL to the CardShock risk score improved discrimination identifying high-risk patients originally categorized in the intermediate-risk category. Conclusion SuPAR associates with mortality and improves risk stratification independently of other previously known risk factors in CS patients.
Dados da publicação
- ISSN/ISSNe:
- 2048-8734, 2048-8726
- Tipo:
- Article
- Páginas:
- 731-738
- Link para outro recurso:
- www.scopus.com
EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE Oxford University Press
Citações Recebidas na Web of Science: 1
Citações Recebidas na Scopus: 4
Documentos
- Não há documentos
Filiações
Keywords
- Cardiogenic shock; suPAR; Risk stratification; Biomarker
Financiamento
Proyectos asociados
Registo global de insuficiência cardíaca congestiva.
Investigador Principal: José Carlos de Magalhães Silva Cardoso
Estudo Observacional Académico (IC_Congestiva) . 2019
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms (EMPERIAL) - NCT03448406
Investigador Principal: José Carlos de Magalhães Silva Cardoso
Ensaio Clínico Comercial (EMPERIAL) . Boehringer Ingelheim . 2020
Envolva-se com o seu coração: Promoção da adesão terapêutica com um sistema de telemonitorização para pessoas com insuficiência cardíaca crónica. (AdHeart)
Investigador Principal: José Carlos de Magalhães Silva Cardoso
Estudo de Intervenção Académico (AdHeart) . FCT . 2019
Sacubitril/Valsartan in everyday clinical practice: the experience of a heart failure clinic
Investigador Principal: José Carlos de Magalhães Silva Cardoso
Estudo Clínico Académico (Sacubitril/Valsartan) . 2020
Avaliação da aorta ascendente em doentes operados a tetralogia de Fallot: implicações no follow-up clínico e imagiológico
Investigador Principal: José Carlos de Magalhães Silva Cardoso
Estudo Clínico Académico . 2020
Hyperkalemia as a limiting factor of Neurohormonal Blockade/Modulation in everyday clinical practice
Investigador Principal: José Carlos de Magalhães Silva Cardoso
Estudo Clínico Académico . 2020
Reversão da remodelagem ventricular na miocardiopatia dilatada idiopática
Investigador Principal: José Carlos de Magalhães Silva Cardoso
Estudo Clínico Académico . 2019
Citar a publicação
Hongisto M,Lassus J,Tarvasmäki T,Sans J,Tolppanen H,Kataja A,Jäntti T,Sabell T,Banaszewski M,Silva J,Parissis J,Jurkko R,Spinar J,Castrén M,Mebazaa A,Masip J,Harjola VP,Network C. Soluble urokinase-type plasminogen activator receptor improves early risk stratification in cardiogenic shock. Eur. Heart J. Acute Cardiovasc. Care. 2022. 11. (10):p. 731-738. IF:4,100. (2).
